Floatz logo

[203Pb]Pb-MP0712

Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)

Molecular Partners AGPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) cohort.

Asset / SponsorPhaseRating
[212pb]pb-mp0712
Molecular Partners AG
Phase 1/2CC
Carboplatin
Phanes Therapeutics
Phase 1/2CC
Atezolizumab
Phanes Therapeutics
Phase 1/2CC
ETOPOSIDE
Phanes Therapeutics
Phase 1/2CC
immunoglobulin H-gamma1_L-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3) and anti-[Homo sapiens DLL3 (delta-like ligand 3, delta like canonical Notch ligand 3)], bispecific;
Phanes Therapeutics
Phase 1/2CC
Peluntamig
Phanes Therapeutics
Phase 1/2CC
ML261
Moonlight Bio, Inc
Phase 1CC

Same molecule, other indications

[203Pb]Pb-MP0712 is also rated in:

large cell neuroendocrine carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
pulmonary large cell neuroendocrine carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
Gastroenteropancreatic NEC (GEP NEC)Dormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →